Last Updated: July 5, 2026

RASAGILINE Drug Patent Profile

Name: RASAGILINE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Rasagiline patents expire, and when can generic versions of Rasagiline launch?

Rasagiline is a drug marketed by Alkem Labs Ltd, Apotex Inc, Aurobindo Pharma Usa, Carnegie, Chartwell Rx, Macleods Pharms Ltd, Micro Labs, Orbion Pharms, Regcon Holdings, Rising, Torrent, and Watson Labs Inc. and is included in twelve NDAs.

The generic ingredient in RASAGILINE is rasagiline mesylate. There are eighteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the rasagiline mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rasagiline

A generic version of RASAGILINE was approved as rasagiline mesylate by ORBION PHARMS on March 15^th, 2016.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for RASAGILINE?
What are the global sales for RASAGILINE?
What is Average Wholesale Price for RASAGILINE?

Summary for RASAGILINE

US Patents:	0
Applicants:	12
NDAs:	12
Drug Prices:	Drug price information for RASAGILINE
What excipients (inactive ingredients) are in RASAGILINE?	RASAGILINE excipients list
DailyMed Link:	RASAGILINE at DailyMed

Drug patent expirations by year for RASAGILINE

Recent Clinical Trials for RASAGILINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Guangzhou Henovcom Bioscience Co. Ltd.	PHASE1
Fujian Medical University Union Hospital	Phase 2/Phase 3
The First Affiliated Hospital of Anhui Medical University	Phase 2/Phase 3

See all RASAGILINE clinical trials

US Patents and Regulatory Information for RASAGILINE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkem Labs Ltd	RASAGILINE MESYLATE	rasagiline mesylate	TABLET;ORAL	201889-001	Oct 30, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Regcon Holdings	RASAGILINE MESYLATE	rasagiline mesylate	TABLET;ORAL	206153-002	Oct 4, 2019	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs Inc	RASAGILINE MESYLATE	rasagiline mesylate	TABLET;ORAL	201823-002	Jul 1, 2013		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Carnegie	RASAGILINE MESYLATE	rasagiline mesylate	TABLET;ORAL	201942-001	Nov 18, 2021	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Apotex Inc	RASAGILINE MESYLATE	rasagiline mesylate	TABLET;ORAL	201950-002	Sep 12, 2013		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Macleods Pharms Ltd	RASAGILINE MESYLATE	rasagiline mesylate	TABLET;ORAL	208866-002	Jun 28, 2024	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Rising	RASAGILINE MESYLATE	rasagiline mesylate	TABLET;ORAL	218163-002	Apr 9, 2024	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.